VANCOUVER, Dec. 5 /PRNewswire-FirstCall/ - QLT Inc. announced today that it will host an analyst conference call on Thursday, December 8, 2005 at 8:30 a.m. Eastern Time to discuss strategic update.
The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-525-6384 (North America) or 780-409-1668 (International) before 8:30 a.m. Eastern Time. A replay of the call will be available via the Internet and also via telephone at 1-888-562-2819 (North America) or 402-220-7737 (International), access code 3208010.
About QLT Inc.
QLT Inc. is a global biopharmaceutical company specializing in developing treatments for cancer, eye diseases and dermatological and urological conditions. We have combined our expertise in the discovery, development, commercialization and manufacture of innovative drug therapies with our unique technology platforms to create highly successful products such as Visudyne(R) and Eligard(R). For more information, visit our web site at www.qltinc.com.
QLT Inc.: ---------- Vancouver, Canada Therese Hayes or Tamara Hicks Telephone: 604-707-7000 or 1-800-663-5486 Visudyne is a registered trademark of Novartis AG. Eligard is a registered trademark of Sanofi-aventis. QLT Inc. is listed on The Nasdaq Stock Market under the trading symbol “QLTI” and on The Toronto Stock Exchange under the trading symbol “QLT.”
QLT Inc.
CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes or Tamara Hicks,Telephone: (604) 707-7000 or 1-800-663-5486 ; To request a free copy ofthis organization’s annual report, please go to http://www.newswire.ca andclick on Tools for Investors.